Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?
Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?
Community PollStarted
Will you use pirtobrutinib after covalent BTKi for a patient with prior cardiac toxicity?
28 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Ohio State University James Cancer Center
Answered on
In the MCL patients treated on the BRUIN trial, treatment was well tolerated in general with a low rate of treatment discontinuation or dose reduction. As far as cardiac toxicities, no grade ≥3 treatment emergent AEs of hypertension were observed. Atrial fibrillation/flutter (AF) was reported in 6 (...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Medical College of Wisconsin
Answered on
As part of a safety analysis, we presented an abstract at ASH 2022 to specifically look at pirtobrutinib in a subset of patients who stopped a prior covalent inhibitor due to a toxicity/intolerance issue. Interestingly, this analysis demonstrated that the majority of patients (nearly 80%) who stoppe...
Join for free or sign in to see the full answer